(2S,4R)-N-((1R)-2-chloro-1-((3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide
Clindamycin phosphate建議使用在患有粉刺、面皰之痤瘡(青春痘)患者。其體外培養皿試驗MICs為0.4mcg/ml，能減少皮膚表面的游離脂肪酸，可完全抑制乳酸桿菌。製成局部外用劑能有效治療痤瘡。
Absorption
Oral
Rapidly absorbed. C max is 2.5 mcg/mL. T max is 45 min. Bioavailability is 90%.
IM
T max is 3 h (adults) and 1 h (children).
IV
C max is 7 to 14 mcg/mL.
Vaginal
About 5% is absorbed (cream); 30% (suppositories).
Distribution
Widely distributed (including bones); no significant levels attained in CSF. Excreted in breast milk.
Metabolism
Rapidly converted to active clindamycin.
Elimination
The t ½ is 2.4 to 3.2 h. About 10% of bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as inactive metabolites.
Special Populations
Renal Function Impairment
The t ½ is increased slightly. Dosage adjustment is not usually needed.
Hepatic Function Impairment
The t ½ is increased slightly. Dosage adjustment is not usually needed.
Elderly
The t ½ is increased slightly. Dosage adjustment is not usually needed.
Erythromycin
May cause antagonism.
Kaolin-pectin antidiarrheals
May delay absorption of clindamycin.
Nondepolarizing neuromuscular blockers
May enhance actions of neuromuscular blocking agents.
2.治療期間明顯地下痢時，即需停藥；嚴重下痢病例，可考慮進行大腸內視鏡檢查。
